We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+24.49%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.63B
AUM Growth
+$415M
Cap. Flow
+$332K
Cap. Flow %
0.01%
Top 10 Hldgs %
37.9%
Holding
228
New
11
Increased
45
Reduced
33
Closed
6

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$17M
2
UNH icon
UnitedHealth
UNH
+$15.3M
3
CVS icon
CVS Health
CVS
+$14M
4
MRNA icon
Moderna
MRNA
+$13.1M
5
EXEL icon
Exelixis
EXEL
+$9.71M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$29.8M
2
AGN
Allergan plc
AGN
+$28M
3
GILD icon
Gilead Sciences
GILD
+$23.5M
4
ILMN icon
Illumina
ILMN
+$16.8M
5
CI icon
Cigna
CI
+$11.9M

Sector Composition

Rank Sector Weight
1 Healthcare 95.26%
2 Real Estate 2.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMGN icon
1
Amgen
AMGN
$209B
$144M 5.49%
611,962
+12,091
+2% +$2.76M
VRTX icon
2
Vertex Pharmaceuticals
VRTX
$122B
$139M 5.27%
477,330
-8,400
-2% -$2.28M
GILD icon
3
Gilead Sciences
GILD
$163B
$122M 4.63%
1,581,026
-307,279
-16% -$23.5M
REGN icon
4
Regeneron Pharmaceuticals
REGN
$77.4B
$117M 4.46%
187,935
+17,057
+10% +$9.68M
JNJ icon
5
Johnson & Johnson
JNJ
$617B
$117M 4.44%
830,031
-8,738
-1% -$1.27M
UNH icon
6
UnitedHealth
UNH
$383B
$82.6M 3.15%
280,151
+53,324
+24% +$15.3M
ILMN icon
7
Illumina
ILMN
$31B
$79.5M 3.03%
220,661
-52,087
-19% -$16.8M
MRK icon
8
Merck
MRK
$321B
$75.1M 2.86%
1,018,128
-53,553
-5% -$4.03M
BIIB icon
9
Biogen
BIIB
$30.7B
$62.5M 2.38%
233,599
-99,136
-30% -$29.8M
BMY icon
10
Bristol-Myers Squibb
BMY
$132B
$57.5M 2.19%
977,505
+132,573
+16% +$7.93M
PFE icon
11
Pfizer
PFE
$142B
$54.2M 2.06%
1,746,002
-172,539
-9% -$5.86M
ABBV icon
12
AbbVie
ABBV
$455B
$52.4M 1.99%
533,725
+192,809
+57% +$17M
CVS icon
13
CVS Health
CVS
$134B
$46.8M 1.78%
719,620
+221,634
+45% +$14M
ABT icon
14
Abbott
ABT
$183B
$44.5M 1.69%
486,250
+19,700
+4% +$1.78M
MDT icon
15
Medtronic
MDT
$110B
$43.6M 1.66%
475,489
+28,478
+6% +$2.73M
ALXN
16
DELISTED
Alexion Pharmaceuticals
ALXN
$43.2M 1.64%
384,709
-28,617
-7% -$3.04M
SGEN
17
DELISTED
Seagen Inc. Common Stock
SGEN
$40.9M 1.56%
240,559
+26,029
+12% +$3.88M
TMO icon
18
Thermo Fisher Scientific
TMO
$214B
$38.4M 1.46%
106,025
-6,000
-5% -$2.01M
LLY icon
19
Eli Lilly
LLY
$1.03T
$34M 1.29%
206,837
-51,832
-20% -$7.96M
INCY icon
20
Incyte
INCY
$24.9B
$33.8M 1.29%
325,053
-107,193
-25% -$10.3M
MRNA icon
21
Moderna
MRNA
$23B
$31.6M 1.2%
492,506
+238,360
+94% +$13.1M
BMRN icon
22
BioMarin Pharmaceuticals
BMRN
$11.7B
$30.3M 1.15%
245,362
-25,251
-9% -$2.51M
SYK icon
23
Stryker
SYK
$133B
$29.6M 1.13%
164,230
+28,435
+21% +$5.25M
DHR icon
24
Danaher
DHR
$138B
$28.2M 1.07%
179,749
– –
NBIX icon
25
Neurocrine Biosciences
NBIX
$18.7B
$25.1M 0.96%
206,150
– –
1
2 3 4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2020 Portfolio in Review

As of Q2 2020, Tekla Capital Management held 228 positions worth $2.63B, up 19% from $2.21B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Tekla Capital Management's Q2 2020 filing shows 11 new, 45 increased, 33 reduced and 6 closed positions. Its largest new stake was Molina Healthcare: 27,536 shares worth $4.9M. The largest sale was Biogen, an estimated $29.8M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q2 2020 buy was Molina Healthcare: 27,536 shares worth $4.9M.
  • Tekla Capital Management added most to AbbVie in Q2 2020, an estimated $17M increase.
  • Tekla Capital Management's biggest Q2 2020 reduction was Biogen, cutting an estimated $29.8M.
  • Tekla Capital Management fully exited Allergan plc in Q2 2020, selling an estimated $28M.
  • Tekla Capital Management's ten largest holdings make up 38% of its $2.63B portfolio in Q2 2020.
  • Tekla Capital Management opened 11 new positions and closed 6 in Q2 2020.
  • Tekla Capital Management's portfolio value rose 19% quarter-over-quarter to $2.63B.

Based on Tekla Capital Management's 13F filing for Q2 2020, filed 13 Aug 2020.